checkAd

     150  0 Kommentare Eurofins Awarded U.S. Government Agreement to Expand National COVID-19 Testing

    Regulatory News:

    Clinical Enterprise, Inc., a Eurofins Scientific (Paris:ERF) company, today announced it has been awarded a U.S. Government agreement to expand national COVID-19 testing. The agreement with the U.S. Department of Health and Human Services, in coordination with the U.S. Department of Defense (DOD), will expand testing opportunities in K-8 schools, underserved populations and congregate settings such as homeless shelters. Eurofins has been awarded the agreement to test up to 24.6 million people in the Northeast and South regions.

    The goals of the government-funded programme are to help identify and minimise asymptomatic transmission, curtail broader community transmission, prevent outbreaks in institutional and community settings, and protect vulnerable individuals and populations.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Eurofins Scientific!
    Long
    48,37€
    Basispreis
    0,92
    Ask
    × 6,25
    Hebel
    Short
    68,51€
    Basispreis
    1,11
    Ask
    × 5,17
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Eurofins U.S. Clinical Diagnostics companies, which operate a network of 20 CLIA-certified labs, have been at the forefront of COVID-19 testing. Eurofins launched its first RT-PCR assay for SARS-CoV-2 in the U.S. on March 13, 2020. The FDA-emergency use authorized assay, developed by Eurofins Viracor, Inc., is ranked one of the most sensitive on the market, according to the FDA’s SARS-CoV-2 Reference Panel.1

    Eurofins’ U.S. COVID-19 programme is centered on pooled surveillance PCR tests, where any positive pools reflex immediately to individual diagnostic testing. This method helps identify positive individuals in a timely manner without the need to re-test. Eurofins’ high ratio pooling (24:1) combines low cost testing with a highly sensitive test, which is ideal for early detection in community and school settings.

    Eurofins will partner with Affinity Empowering, Inc., a leading provider of the most sophisticated and secure occupational, behavioral, and direct-to-consumer health services, to scale school and community outreach across both regions. Affinity has developed a fully integrated, HIPAA-compliant technology platform, Assure, which will be used as the end-to-end platform to provide up-to-the-minute scheduling, test results, and reports.

    Eurofins was one of 187 vendors vying for the national COVID-19 testing agreement, which was awarded on May 25th. Outreach to schools and community- based organizations will begin immediately.

    Notes to Editors:

    About Eurofins – the global leader in bio-analysis

    Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

    Seite 1 von 2


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Eurofins Awarded U.S. Government Agreement to Expand National COVID-19 Testing Regulatory News: Clinical Enterprise, Inc., a Eurofins Scientific (Paris:ERF) company, today announced it has been awarded a U.S. Government agreement to expand national COVID-19 testing. The agreement with the U.S. Department of Health and Human …